Athena Drug Delivery Solutions Private Limited — Meloxicam Exporter Profile

Geopolitical & Trade Policy Impact on Athena Drug Delivery Solutions Private Limited's Meloxicam Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Athena. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing significant delays and increased freight costs. These maritime disruptions have the potential to impact up to $600 million in Indian pharmaceutical exports to the West Asia and North Africa (WANA) region, a critical market for generic drug manufacturers. (pharmaceuticalcommerce.com)

Conversely, escalating US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the US market. However, the imposition of tariffs on pharmaceutical imports by the US poses a threat to this opportunity. In August 2025, the US administration imposed broad tariffs on imports from over 60 countries, including India, with rates reaching as high as 39%. These tariffs could significantly impact Indian exporters, as nearly 55% of the country's outbound shipments to America are affected. (apnews.com)

In the European Union, regulatory changes such as the Falsified Medicines Directive (FMD) have introduced stringent compliance requirements. Indian exporters must adapt to these evolving standards to maintain market access. The India–EFTA Trade and Economic Partnership Agreement, effective from October 2025, aims to eliminate or reduce tariffs on goods traded between India and EFTA countries, potentially benefiting companies like Athena. (en.wikipedia.org)